Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sjögren's syndrome

Clinical and Experimental Immunology

Volumn 177, Issue 3, 2014, Pages 618-629

  Vartoukian, S R ^a   Tilakaratne, W M ^b   Seoudi, N ^a   Bombardieri, M ^a   Bergmeier, L ^a   Tappuni, A R ^a   Fortune, F ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF PERADENIYA   (Sri Lanka)

Author keywords

IL 17; Pathogenesis; Sj gren's syndrome; SOCS 3; STAT 3

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SALIVARY GLAND; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; UPREGULATION;

IL-17; PATHOGENESIS; SJÖGREN'S SYNDROME; SOCS-3; STAT-3;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84904740659     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12377     Document Type: Article

References (48)

1. Vitali C, Bombardieri S, Jonsson R etal. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-558.
2. Youinou P, Pers JO. Disturbance of cytokine networks in Sjogren's syndrome. Arthritis Res Ther 2011; 13:227. doi:10.1186/ar3348.
3. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051-1057.
4. Lee BH, Tudares MA, Nguyen CQ. Sjogren's syndrome: an old tale with a new twist. Arch Immunol Ther Exp 2009; 57:57-66.
5. Mariette X, Gottenberg JE. Pathogenesis of Sjogren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010; 22:471-477.
6. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol 2010; 6:529-537.
7. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009; 175:1167-1177.
8. Mieliauskaite D, Dumalakiene I, Rugiene R, Mackiewicz Z. Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjogren's syndrome. Clin Dev Immunol 2012; 2012:187258. doi:10.1155/2012/187258.
9. Ciccia F, Guggino G, Rizzo A etal. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012; 71:295-301.
10. Kang EH, Lee YJ, Hyon JY, Yun PY, Song YW. Salivary cytokine profiles in primary Sjogren's syndrome differ from those in non-Sjogren sicca in terms of TNF-alpha levels and Th-1/Th-2 ratios. Clin Exp Rheumatol 2011; 29:970-976.
11. Nguyen CQ, Yin H, Lee BH, Carcamo WC, Chiorini JA, Peck AB. Pathogenic effect of interleukin-17A in induction of Sjogren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther 2010; 12:R220.
12. Lin X, Rui K, Deng J etal. Th17 cells play a critical role in the development of experimental Sjogren's syndrome. Ann Rheum Dis 2014. doi:10.1136/annrheumdis-2013-204584. [Epub ahead of print]
13. Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB. IL17: potential therapeutic target in Sjogren's syndrome using adenovirus-mediated gene transfer. Lab Invest 2011; 91:54-62.
14. Piessevaux J, Lavens D, Peelman F, Tavernier J. The many faces of the SOCS box. Cytokine Growth Factor Rev 2008; 19:371-381.
15. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 2011; 31:980-985.
16. Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 2009; 30:592-602.
17. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28:477-487.
18. Yoshimura A. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J Med 2008; 58:73-83.
19. Babon JJ, Nicola NA. The biology and mechanism of action of suppressor of cytokine signaling 3. Growth Factors 2012; 30:207-219.
20. Babon JJ, Kershaw NJ, Murphy JM etal. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 2012; 36:239-250.
21. Chaves de Souza J, Nogueira A, Chaves de Souza P etal. SOCS3 expression correlates with severity of inflammation, expression of proinflammatory cytokines, and activation of STAT3 and p38 MAPK in LPS-induced inflammation in vivo. Mediat Inflamm 2013; 2013:1-10.
22. Qin H, Wang L, Feng T etal. TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol 2009; 183:97-105.
23. Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 2010; 21:413-423.
24. Yang XO, Panopoulos AD, Nurieva R etal. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007; 282:9358-9363.
25. Chen Z, Laurence A, Kanno Y etal. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006; 103:8137-8142.
26. Ogata H, Chinen T, Yoshida T etal. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006; 25:2520-2530.
27. Cao W, Yang Y, Wang Z etal. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity 2011; 35:273-284.
28. Taleb S, Romain M, Ramkhelawon B etal. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009; 206:2067-2077.
29. Wong PK, Egan PJ, Croker BA etal. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 2006; 116:1571-1581.
30. Veenbergen S, Bennink MB, de Hooge AS etal. Splenic suppressor of cytokine signaling 3 transgene expression affects T cell responses and prevents development of collagen-induced arthritis. Arthritis Rheum 2008; 58:3742-3752.
31. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008; 181:2898-2906.
32. da Silva JC, Mariz HA, da Rocha LF Jr etal. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (São Paulo) 2013; 68:766-771.
33. Smeekens SP, van de Veerdonk FL, van der Meer JW, Kullberg BJ, Joosten LA, Netea MG. The Candida Th17 response is dependent on mannan- and beta-glucan-induced prostaglandin E2. Int Immunol 2010; 22:889-895.
34. Pflegerl P, Vesely P, Hantusch B etal. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci USA 2009; 106:20423-20428.
35. Federici M, Giustizieri ML, Scarponi C, Girolomoni G, Albanesi C. Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1. J Immunol 2002; 169:434-442.
36. Isomaki P, Alanara T, Isohanni P etal. The expression of SOCS is altered in rheumatoid arthritis. Rheumatology (Oxf) 2007; 46:1538-1546.
37. Lovato P, Brender C, Agnholt J etal. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003; 278:16777-16781.
38. Takase H, Yu CR, Liu X, Fujimoto C, Gery I, Egwuagu CE. Induction of suppressors of cytokine signaling (SOCS) in the retina during experimental autoimmune uveitis (EAU): potential neuroprotective role of SOCS proteins. J Neuroimmunol 2005; 168:118-127.
39. Berger H, Vegran F, Chikh M etal. SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth. Cancer Res 2013; 73:3578-3590.
40. Bode C, Yang XP, Kiu H, Klinman DM. Suppressive oligodeoxynucleotides promote the development of Th17 cells. PLOS ONE 2013; 8:e67991.
41. Correale J, Farez MF. Parasite infections in multiple sclerosis modulate immune responses through a retinoic acid-dependent pathway. J Immunol 2013; 191:3827-3837.
42. Romain M, Taleb S, Dalloz M etal. Overexpression of SOCS3 in T lymphocytes leads to impaired interleukin-17 production and severe aortic aneurysm formation in mice-brief report. Arterioscler Thromb Vasc Biol 2013; 33:581-584.
43. Kleinsteuber K, Heesch K, Schattling S etal. SOCS3 promotes interleukin-17 expression of human T cells. Blood 2012; 120:4374-4382.
44. Shouda T, Yoshida T, Hanada T etal. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001; 108:1781-1788.
45. Ramos HL, Valencia-Pacheco G, Alcocer-Varela J. Constitutive STAT3 activation in peripheral CD3(+) cells from patients with primary Sjogren's syndrome. Scand J Rheumatol 2008; 37:35-39.
46. Kershaw NJ, Murphy JM, Liau NP etal. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 2013; 20:469-476.
47. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72 (Suppl. 2):ii111-115.
48. Soyfoo MS, Catteau X, Delporte C. Parotid gland biopsy as an additional diagnostic tool for supporting the diagnosis of Sjogren's syndrome. Int J Rheumatol 2011; 2011:302527.